IMGN529 is an anti-CD37-maytansinoid conjugate with potent in vitro and in vivo activity against NHL and CLL cell lines

被引：0

|

作者：

Mayo, Michele F. ^{[1
]}

Li, Min ^{[1
]}

Yi, Yong ^{[1
]}

Xu, Shanqin ^{[1
]}

Lai, Katharine C. ^{[1
]}

Erickson, Hans K. ^{[1
]}

Deckert, Jutta ^{[1
]}

Park, Peter U. ^{[1
]}

Lutz, Robert J. ^{[1
]}

Pinkas, Jan ^{[1
]}

机构：

[1] ImmunoGen Inc, Waltham, MA USA

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/1538-7445.AM2011-4581

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4581

引用

收藏

页数：2

相关论文

共 43 条

[41] The novel ICAM-1/CD54 antibody MSH-TP15, identified by a cell-based phage display screening approach, has potent anti-myeloma activity in vitro and in vivo
Klausz, K.
Burger, R.
Kellner, C.
Peipp, M.
Gramatzki, M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 201 - 201
[42] Anti-CD20-interferon-alpha fusion protein has superior in vivo activity against human B-cell lymphomas compared to rituximab and enhanced complement-dependent cytotoxicity in vitro
Yamada, Reiko E.
Steward, Kristopher K.
Ngarmchamnanrith, Gataree
Trinh, Ryan K.
Khare, Sanjay
Sachdev, Raj
Grewal, Iqbal S.
Morrison, Sherie L.
Timmerman, John
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[43] Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL)
Barth, Matthew
Hernandez-Ilizaliturri, Francisco J.
Mavis, Cory
Tsai, Ping-Chiao
Gibbs, John
Deeb, George
Czuczman, Myron S.
BLOOD, 2010, 116 (21) : 1598 - 1598

← 1 2 3 4 5 →